Trials / Completed
CompletedNCT02947165
Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.
A Phase I/Ib, Open-label, Multi-center Dose Escalation Study of NIS793 in Combination With PDR001 in Adult Patients With Advanced Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To characterize the safety and tolerability of NIS793 as single agent and in combination with PDR001 and to identify recommended doses for future studies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NIS793 | Anti-TGF beta antibody tested on a Q3W regimen or alternative Q2W regimen. |
| DRUG | PDR001 | Anti-PD-1 antibody tested on a Q3W regimen or alternative Q4W regimen. |
Timeline
- Start date
- 2017-04-25
- Primary completion
- 2021-06-18
- Completion
- 2021-06-18
- First posted
- 2016-10-27
- Last updated
- 2022-01-31
Locations
12 sites across 9 countries: United States, Austria, Canada, Germany, Hong Kong, Italy, Japan, Switzerland, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02947165. Inclusion in this directory is not an endorsement.